Linda Skelcy v. UnitedHealth Group Inc

620 F. App'x 136
CourtCourt of Appeals for the Third Circuit
DecidedSeptember 22, 2015
Docket15-1012
StatusUnpublished
Cited by2 cases

This text of 620 F. App'x 136 (Linda Skelcy v. UnitedHealth Group Inc) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Linda Skelcy v. UnitedHealth Group Inc, 620 F. App'x 136 (3d Cir. 2015).

Opinion

OPINION *

JORDAN, Circuit Judge.

Appellant Linda Skelcy, in her individual capacity and as the administratrix of the estate of her husband, James Skelcy, asks us to reverse an order of the United States District Court for the District of New Jersey dismissing her complaint against Medical Evaluation Specialists, Inc. (“MES”) and' Dr. Denise Beighe, M.D (“Dr. Beighe”). Because we agree with the District Court that neither MES nor Dr. Beighe owed a duty of care to Mr. Skelcy, we will affirm.

I. Background

*138 A. Factual Background 1

In July of 2007, Mr. Skelcy was diagnosed with dermatomyositis, a connective tissue disease. Later, he was diagnosed with interstitial lung disease (“ILD”), as a secondary condition. At all relevant times, Mr. Skelcy was covered by a health insurance policy issued by UnitedHealth Group, Inc. (“UnitedHealth”), by and through Oxford Health Insurance, Inc. (“Oxford”).

Mr. Skelcy was first treated with various first-line medications, but they proved ineffective. Then, in August 2009, his treating rheumatologist prescribed Rituxi-mab (“Rituxan”), a common next-step therapy. UnitedHealth and Oxford (collectively “the UnitedHealth Defendants”) approved and covered Mr. Skelcy’s Ritux-an treatments without delay or question. Mr. Skelcy received two doses of the drug, to which he responded very well. In fact, he responded so positively that he was able to maintain remission of his dermato-myositis and ILD for almost one full year with those two doses of Rituxan.

In July 2010, his symptoms returned. His treating rheumatologist immediately prescribed another dose of Rituxan, which was scheduled to be administered later that month. But, two days before the scheduled treatment, the UnitedHealth Defendants had still not approved the dose of Rituxan. Mr. Skelcy’s treating rheuma-tologist therefore faxed a letter of medical necessity to Oxford expressing Mr. Skel-cy’s urgent need for a dose of Rituxan or an intravenous immunoglobin (“IVIG”) infusion. The imminent need for one of the treatments was or should have been immediately apparent to the UnitedHealth Defendants, given Mr. Skelcy’s deteriorating condition and prior response to Rituxan. Nevertheless, on the same day that they received the fax, the UnitedHealth Defendants denied the claim for Rituxan or an IVIG infusion. Mr. Skelcy’s treating rheu-matologist had numerous follow-up conversations with the UnitedHealth Defendants’ representatives in which he explained the need for treatment. He also immediately responded by filing an “Expedited Utilization Review Appeal,” as permitted by Mr. Skelcy’s insurance policy.

Within two days of receiving the clinical information necessary to process the expedited appeal, the UnitedHealth Defendants transmitted the appeal to MES for a peer review assessment. MES assigned Dr. Beighe, a rheumatologist located and licensed in Arizona, to provide the peer review assessment of the expedited appeal. 2 After reviewing the materials pro *139 vided by Mr. Skelcy’s treating rheumatologist, including medical records indicating that Mr. Skelcy had previously responded well to Rituxan, Dr. Beighe stated in her peer review assessment that, “[t]his type of therapy is not [the] standard of care for this disease” and “[t]his specific therapy is not [the] standard of care for this patient’s disease.” (App: at 49.) Dr. Beighe further specified that there was inadequate medical literature to conclude that Rituxan was effective in treating Mr. Skelcy’s condition, but she also concluded that “IVIG would be [the] standard of care at this point for the member.” (Id.)

The next day after receiving Dr. Beighe’s assessment, the UnitedHealth Defendants again denied the request to treat Mr. Skelcy with Rituxan or an IVIG infusion. In an internal memorandum, the UnitedHealth Defendants stated, “[a] board certified rheumatologist has reviewed the request and has [determined] that the request for Rituxan should be denied as unproved. The clinical data from the prevailing peer reviewed published medical literature is not adequate to conclude that the requested medication is effective in treating the member’s condition.” (App. at 50.) Despite Dr. Beighe’s specific recommendation in favor of an IVIG infusion, the UnitedHealth Defendants did not approve that therapy.

Approximately two weeks after the denial of Mr. Skelcy’s expedited appeal, his treating rheumatologist faxed a letter to the UnitedHealth Defendants pleading that Mr. Skelcy had received Rituxan in August 2009 “with excellent response,” and stating that the “patient is a father, is a husband, and the main bread winner of his familjr” and that “[a] further deterioration of his condition ... is imminent.” (App. at 50-51.) On August 9, 2010, thirty-two days after receiving Mr. Skelcy’s claim for treatment, the UnitedHealth Defendants reversed their decision and approved the Rituxan treatment. The record reveals no explanation for their tragically belated change of heart. Within 36 hours of the UnitedHealth Defendants’ decision to approve the Rituxan treatment, Mr. Skelcy died. The Union County Medical Examiner’s Office determined that the cause of death was chronic dermatomyositis, interstitial pulmonary fibrosis, endomyocar-dial fibrosis, and cardiac arrhythmia.

B. PROCEDURAL HISTORY

Mrs. Skelcy filed her First Amended Complaint on April 13, 2012, asserting, inter alia, claims for negligence and negligence per se against MES and Dr. Beighe. On June 29, 2012, MES and Dr. Beighe filed a motion to dismiss all claims against them, advancing three arguments: (1) neither owed a duty of care to Mr. Skelcy; (2) the statute underlying the negligence per se claims did not impose a duty upon them; and (3) the court lacked personal jurisdiction over Dr. Beighe. Mrs. Skelcy responded by filing a motion for leave to file a Second Amended Complaint, withdrawing the negligence per se claims. She also opposed MES’s and Dr. Beighe’s motion to dismiss the negligence claims.

The District Court granted MES’s and Dr. Beighe’s motion to dismiss, reasoning that “there is both a lack of a demonstrable duty to Mr. Skelcy on the part of [MES or Dr. Beighe] and of causation.” (Id. at 22.) The Court said that, because neither MES nor Dr. Beighe had a special or contractual relationship with Mr. Skel-cy, “there exists no grounds for traditional *140 medical malpractice [or negligence] claims against Dr. Beighe” or MES. (Id.) Moreover, given that neither MES nor Dr. Beighe set the standard for review in the UnitedHealth Defendants’ treatment approval process or made the final judgment on treatment certification, the District Court found no “sufficient nexus between the actions of [MES or Dr. Beighe] and Mr. Skelcy’s death.” (Id.) The District Court also denied Mrs. Skelcy’s motion to amend her remaining claims against MES and Dr. Beighe, stating that any motion to amend the remaining' negligence claims would be futile. 3

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
620 F. App'x 136, Counsel Stack Legal Research, https://law.counselstack.com/opinion/linda-skelcy-v-unitedhealth-group-inc-ca3-2015.